BioCentury
ARTICLE | Clinical News

VAX100: Phase I/II data

January 9, 2006 8:00 AM UTC

Two-year follow-up data from an open-label, U.S. and Italian Phase I/II study in 18 evaluable patients, who had stable residual disease and showed no improvement for a minimum of 12 months after treat...